AIP
NVS icon

Arrowpoint Investment Partners’s Novartis NVS Stock Holding History

Arrowpoint Investment Partners’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,600
Closed -$401K – 615
2025
Q1 		$401K Buy
+3,600
New +$383K 0.05% 440

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowpoint Investment Partners's NVS Position: Q1 2026 in Review

Arrowpoint Investment Partners sold out of Novartis (NVS) in Q1 2026, closing a stake of 6,200 shares — an estimated $855K sold.

Arrowpoint Investment Partners first reported a position in NVS in Q4 2025 and held it in 1 quarter. The position peaked at $855K in Q4 2025. 1,597 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Arrowpoint Investment Partners reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 6,200 Novartis shares in Q1 2026, an estimated $855K.
  • Arrowpoint Investment Partners first reported a position in Novartis in Q4 2025 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Novartis position peaked at $855K in Q4 2025.
  • 1,597 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.